This company has been marked as potentially delisted and may not be actively trading. Merus (MRUS) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Get the Latest News and Ratings for MRUS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Merus and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRUS Analyst Ratings Over TimeTypeCurrent Forecast5/19/25 to 5/19/261 Month Ago4/19/25 to 4/19/263 Months Ago2/18/25 to 2/18/261 Year Ago5/19/24 to 5/19/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)2 Strong Buy rating(s)Buy1 Buy rating(s)1 Buy rating(s)2 Buy rating(s)13 Buy rating(s)Hold13 Hold rating(s)13 Hold rating(s)13 Hold rating(s)0 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)0 Sell rating(s)Consensus Price Target$95.93$95.93$94.20$84.54Forecasted Upside6.59% Upside6.59% Upside4.67% Upside104.40% UpsideConsensus RatingHoldHoldHoldBuy MRUS Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History MRUS Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Merus Stock vs. The CompetitionTypeMerusMedical CompaniesBroader MarketConsensus Rating Score 2.00 2.30 2.52Consensus RatingHoldHoldModerate BuyPredicted Upside6.59% Upside1,733.11% Upside17.33% UpsideNews Sentiment RatingNeutral NewsSee Recent MRUS NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/31/2025 BMO Capital Markets4 of 5 starsEvan David SeigermanNot RatedReiterated RatingMarket Perform$97.00+2.05%10/8/2025 Weiss RatingsNot Rated Reiterated RatingSell (D-)10/6/2025 Leerink Partners2 of 5 starsAndrew Berens5 of 5 starsReiterated RatingOutperform ➝ Market Perform$95.00 ➝ $97.00+2.87%9/30/2025 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid DaiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Neutral$72.00 ➝ $97.00+3.56%9/30/2025 BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEtzer DaroutSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$112.00 ➝ $97.00+3.56%9/30/2025 GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMichael SchmitzSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$109.00 ➝ $97.00+3.62%9/30/2025 Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingCharles ZhuSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$97.00+3.56%9/29/2025 HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndres Y. MaldonadoSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Neutral$135.00 ➝ $97.00+3.52%9/29/2025 Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJohn NewmanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Hold$67.00 ➝ $97.00+3.68%9/29/2025 William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeStrong-Buy ➝ Hold Get the Latest News and Ratings for MRUS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Merus and its competitors with MarketBeat's FREE daily newsletter. 9/29/2025 Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAsthika GoonewardeneSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Hold$88.00 ➝ $97.00+3.41%9/29/2025 Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEva Fortea-VerdejoSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$95.00 ➝ $97.00+3.03%9/29/2025 Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAmi FadiaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Hold$96.00+1.97%9/29/2025 CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingYigal NochomovitzSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Neutral$101.00 ➝ $97.00+40.80%8/25/2025 iA FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Set Target$90.00+36.36%8/25/2025 Alliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMatt VeneziaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy$90.00+33.35%3/10/2025 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingTazeen AhmadSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$73.00 ➝ $70.00+52.25%2/13/2025 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJoseph CatanzaroSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOverweight$84.00+108.64%11/21/2024 The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRichard LawSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy$73.00+70.04%6/17/2024 Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$90.00 ➝ $99.00+75.07%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:57 PM ET. MRUS Forecast - Frequently Asked Questions What is Merus' forecast for 2026? According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Merus is $95.93, with a high forecast of $97.00 and a low forecast of $90.00. Should I buy or sell Merus stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Merus in the last twelve months. There is currently 1 sell rating, 13 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRUS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRUS, but not buy additional shares or sell existing shares. Does Merus's stock price have much upside? According to analysts, Merus's stock has a predicted upside of 6.59% based on their 12-month stock forecasts. Do Wall Street analysts like Merus more than its competitors? Analysts like Merus less than other "medical" companies. The consensus rating score for Merus is 2.00 while the average consensus rating score for "medical" companies is 2.30. Learn more on how MRUS compares to other companies. Stock Forecasts and Research Tools Related Companies BioNTech Stock Forecast Insmed Stock Forecast Moderna Stock Forecast Roivant Sciences Stock Forecast Viatris Stock Forecast Genmab A/S Stock Forecast Ascendis Pharma A/S Stock Forecast Regencell Bioscience Stock Forecast Summit Therapeutics Stock Forecast BridgeBio Pharma Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Merus RecommendationsBMO Capital MarketsWeiss RatingsLeerink PartnersBarclaysGuggenheimLifesci CapitalUBS GroupNeedham & Company LLCWells Fargo & CompanyHC WainwrightTruist FinancialCitigroupCanaccord Genuity GroupWilliam BlairiA Financial This page (NASDAQ:MRUS) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.